| Description |
1 online resource. |
| Physical Medium |
polychrome |
| Description |
text file |
| Series |
IAEA human health series ; no. 38
|
|
IAEA human health series ; no. 38.
|
| Contents |
Intro -- 1. INTRODUCTION -- 1.1. Background -- 1.2. Objective -- 1.3. Scope -- 1.4. Structure -- 2. ACETATE (11C) -- 2.1. General characteristics -- 2.2. Pharmacokinetics -- 2.2.1. Physiological biodistribution and metabolism -- 2.2.2. Mechanism of retention -- 2.2.3. Pharmacology and toxicology -- 2.3. Methodology -- 2.3.1. Activity, administration, dosimetry -- 2.3.2. Imaging protocol -- 2.4. Clinical aspects -- 2.4.1. Indications -- 3. Bevacizumab (89Zr) -- 3.1. General characteristics -- 3.2. Pharmacokinetics -- 3.2.1. Metabolism -- 3.2.2. Mechanism of retention |
|
3.2.3. Pharmacology and toxicology -- 3.3. Methodology -- 3.3.1. Activity, administration, dosimetry -- 3.3.2. Imaging protocol -- 3.4. Clinical aspects -- 3.4.1. Indications -- 4. Choline (11C) -- 4.1. General characteristics -- 4.2. Pharmacokinetics -- 4.2.1. Physiological biodistribution and metabolism -- 4.2.2. Mechanism of retention -- 4.2.3. Pharmacology and toxicology -- 4.3. Methodology -- 4.3.1. Activity, administration, dosimetry -- 4.3.2. Imaging protocol -- 4.4. Clinical aspects -- 4.4.1. Indications -- 5. Choline (18F) -- 5.1. General characteristics -- 5.2. Pharmacokinetics |
|
5.2.1. Physiological biodistribution and metabolism -- 5.2.2. Mechanism of retention -- 5.2.3. Pharmacology and toxicology -- 5.3. Methodology -- 5.3.1. Activity, administration, dosimetry -- 5.3.2. Imaging protocol -- 5.4. Clinical aspects -- 5.4.1. Indications -- 6. FLUORO-DIHYDROTESTOSTERONE -- FDHT (18F) -- 6.1. General characteristics -- 6.2. Pharmacokinetics -- 6.2.1. Physiological biodistribution and metabolism -- 6.2.2. Mechanism of retention -- 6.2.3. Pharmacology and toxicology -- 6.3. Methodology -- 6.3.1. Activity, administration, dosimetry -- 6.3.2. Imaging protocol |
|
6.4. Clinical aspects -- 6.4.1. Indications -- 7. F-DOPA (18F) -- 7.1. General characteristics -- 7.2. Pharmacokinetics -- 7.2.1. Physiological biodistribution and metabolism -- 7.2.2. Mechanism of retention -- 7.3. Methodology -- 7.3.1. Activity, administration, dosimetry -- 7.3.2. Imaging protocol -- 7.4. Clinical aspects -- 7.4.1. Indications -- 8. Fluoroestradiol, FES (18F) -- 8.1. General characteristics -- 8.2. Pharmacokinetics -- 8.2.1. Physiological biodistribution and metabolism -- 8.2.2. Mechanism of retention -- 8.2.3. Pharmacology and toxicology -- 8.3. Methodology |
|
8.3.1. Activity, administration, dosimetry -- 8.3.2. Imaging protocol -- 8.4. Clinical aspects -- 8.4.1. Indications -- 9. Fluoroethyl-tyrosine, FET (18F) -- 9.1. General characteristics -- 9.2. Pharmacokinetics -- 9.2.1. Physiological biodistribution and metabolism -- 9.2.2. Mechanism of retention -- 9.2.3. Pharmacology and toxicology -- 9.3. Methodology -- 9.3.1. Activity, administration, dosimetry -- 9.3.2. Imaging protocol -- 9.4. Clinical aspects -- 9.4.1. Indications -- 10. FLUOROTHYMIDINE, FLT (18F) -- 10.1. General characteristics -- 10.2. Pharmacokinetics |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Tomography, Emission.
|
|
Tomography, Emission. |
|
Tomography.
|
|
Tomography. |
|
Cancer -- Radionuclide imaging.
|
|
Cancer -- Radionuclide imaging. |
|
Oncology.
|
|
Oncology. |
| Genre/Form |
Electronic books.
|
|
Electronic books.
|
| ISBN |
9789201291202 (electronic book) |
|
9201291205 (electronic book) |
|
